Azevan Pharmaceuticals Inc (AKA: Serenix Pharmaceuticals Inc) Profile last edited on: 7/1/2019
CAGE: 473U1
UEI: VHSKTKSAY2S1
Business Identifier: Therapeutics to treat disorders of stress, mood, and behavior Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Northampton
Congr. District: 07
County: Northampton
Public Profile
Formerly known as Serenix Pharmaceuticals, LLC with the name-change to Azevan Pharmaceuticals, Inc. in early 2002, the firm is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. Developing new molecules that address significant unmet needs in psychiatry through a novel mechanism of action, the Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. The Companys first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 2 | NIH | $8,825,991 | |
Project Title: Tolerability of SRX246 in Huntington's Disease Patients | ||||
2019 | 1 | NIH | $501,472 | |
Project Title: A New Drug for the Treatment of Traumatic Brain Injury | ||||
2013 | 2 | NIH | $2,258,270 | |
Project Title: New Drugs For Stress-Related Affective Illness | ||||
2011 | 1 | NIH | $141,071 | |
Project Title: Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder | ||||
2009 | 2 | NIH | $4,517,005 | |
Project Title: A New Drug for Depression |
Key People / Management
Neal G Simon -- CEO
Michael J Brownstein
Eve M Damiano -- VP Operations
Gary A Koppel
Michael J Brownstein
Eve M Damiano -- VP Operations
Gary A Koppel